Surmodics, Inc. (NASDAQ:SRDX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Friday.
SRDX has been the subject of several other reports. Aegis initiated coverage on shares of Surmodics in a research note on Tuesday, June 27th. They issued a “buy” rating for the company. Zacks Investment Research downgraded shares of Surmodics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. ValuEngine downgraded shares of Surmodics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Lake Street Capital initiated coverage on shares of Surmodics in a research note on Friday, July 14th. They issued a “buy” rating and a $40.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.33.
Shares of Surmodics (SRDX) traded up 0.61% during mid-day trading on Friday, hitting $24.65. 11,887 shares of the stock were exchanged. The company has a 50-day moving average of $26.95 and a 200 day moving average of $24.78. Surmodics has a one year low of $21.90 and a one year high of $30.75. The stock has a market cap of $323.14 million, a PE ratio of 53.70 and a beta of 0.88.
Surmodics (NASDAQ:SRDX) last announced its earnings results on Thursday, August 3rd. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.10. The business had revenue of $17.80 million during the quarter, compared to the consensus estimate of $15.98 million. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.37 earnings per share. On average, equities analysts predict that Surmodics will post $0.27 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2801843/bidaskclub-downgrades-surmodics-inc-nasdaqsrdx-to-sell.html.
In other Surmodics news, VP Joseph J. Stich sold 1,000 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $25.31, for a total transaction of $25,310.00. Following the transaction, the vice president now directly owns 40,672 shares in the company, valued at approximately $1,029,408.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Gary R. Maharaj sold 5,000 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $28.03, for a total transaction of $140,150.00. Following the transaction, the chief executive officer now owns 131,807 shares in the company, valued at $3,694,550.21. The disclosure for this sale can be found here. Insiders have sold a total of 14,928 shares of company stock worth $392,469 over the last quarter. 6.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Tennessee Treasury Department increased its position in Surmodics by 17.8% in the first quarter. State of Tennessee Treasury Department now owns 12,786 shares of the company’s stock worth $308,000 after buying an additional 1,930 shares during the period. Principal Financial Group Inc. increased its position in Surmodics by 4.0% in the first quarter. Principal Financial Group Inc. now owns 102,916 shares of the company’s stock worth $2,475,000 after buying an additional 3,978 shares during the period. State Street Corp increased its position in Surmodics by 10.8% in the fourth quarter. State Street Corp now owns 313,462 shares of the company’s stock worth $7,962,000 after buying an additional 30,557 shares during the period. Trigran Investments Inc. increased its position in Surmodics by 52.4% in the first quarter. Trigran Investments Inc. now owns 1,070,499 shares of the company’s stock worth $25,745,000 after buying an additional 368,212 shares during the period. Finally, Renaissance Technologies LLC increased its position in Surmodics by 4.0% in the first quarter. Renaissance Technologies LLC now owns 1,002,721 shares of the company’s stock worth $24,115,000 after buying an additional 38,683 shares during the period. Hedge funds and other institutional investors own 84.83% of the company’s stock.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.